Evidence map›Paper›PMID 35740228›Full record

ArticleAntibiotics (Basel, Switzerland)2022

Effect of Fluoroquinolone Use in Primary Care on the Development and Gradual Decay of

Peter Konstantin Kurotschka, Chiara Fulgenzio, Roberto Da Cas, Giuseppe Traversa, Gianluigi Ferrante, Orietta Massidda, Ildikó Gágyor, Richard Aschbacher, Verena Moser, Elisabetta Pagani and 2 more

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Peter Konstantin KurotschkaDepartment of General Practice, University Hospital Wuerzburg, Josef-Schneider-Str. 2, 97080 Wuerzburg, Germany.ORCID 0000-0003-3750-6147
Chiara FulgenzioPharmacy Unit, IRCCS Regina Elena National Cancer Institute and San Gallicano Institute, 00128 Rome, Italy.ORCID 0000-0002-3569-9523
Roberto Da CasPharmacoepidemiology and Pharmacovigilance Unit, National Centre for Drug Research and Evaluation, Italian National Institute of Health (ISS), 00161 Rome, Italy.
Giuseppe TraversaPharmacoepidemiology and Pharmacovigilance Unit, National Centre for Drug Research and Evaluation, Italian National Institute of Health (ISS), 00161 Rome, Italy.
Gianluigi FerranteAzienda Ospedaliera-Universitaria Città della Salute e della Scienza di Torino, 10126 Turin, Italy.
Orietta MassiddaDepartment of Cellular, Computational and Integrative Biology, Center of Medical Sciences (CISMed), University of Trento, 38122 Trento, Italy.ORCID 0000-0001-8823-2372
Ildikó GágyorDepartment of General Practice, University Hospital Wuerzburg, Josef-Schneider-Str. 2, 97080 Wuerzburg, Germany.
Richard AschbacherHealth Service of the Autonomous Province of Bolzano/Bozen, 39100 Bolzano/Bozen, Italy.
Verena MoserHealth Service of the Autonomous Province of Bolzano/Bozen, 39100 Bolzano/Bozen, Italy.
Elisabetta PaganiHealth Service of the Autonomous Province of Bolzano/Bozen, 39100 Bolzano/Bozen, Italy.
Stefania Spila AlegianiPharmacoepidemiology and Pharmacovigilance Unit, National Centre for Drug Research and Evaluation, Italian National Institute of Health (ISS), 00161 Rome, Italy.ORCID 0000-0003-0656-1346
Marco MassariPharmacoepidemiology and Pharmacovigilance Unit, National Centre for Drug Research and Evaluation, Italian National Institute of Health (ISS), 00161 Rome, Italy.ORCID 0000-0001-8442-4238
Istituto Superiore di Sanità · ITOspedale di Bolzano · ITUniversitätsklinikum Würzburg · DEAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITSan Gallicano Hospital · ITUniversity of Trento · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The reversibility of bacterial resistance to antibiotics is poorly understood. Therefore, the aim of this study was to determine, over a period of five years, the effect of fluoroquinolone (FQ) use in primary care on the development and gradual decay of Escherichia coli resistance to FQ. In this matched case−control study, we linked three sources of secondary data of the Health Service of the Autonomous Province of Bolzano, Italy. Cases were all those with an FQ-resistant E. coli (QREC)-positive culture from any site during a 2016 hospital stay. Data were analyzed using conditional logistic regression. A total of 409 cases were matched to 993 controls (FQ-sensitive E. coli) by the date of the first isolate. Patients taking one or more courses of FQ were at higher risk of QREC colonization/infection. The risk was highest during the first year after FQ was taken (OR 2.67, 95%CI 1.92−3.70, p < 0.0001), decreased during the second year (OR 1.54, 95%CI 1.09−2.17, p = 0.015) and became undetectable afterwards (OR 1.09, 95%CI 0.80−1.48, p = 0.997). In the first year, the risk of resistance was highest after greater cumulative exposure to FQs. Moreover, older age, male sex, longer hospital stays, chronic obstructive pulmonary disease (COPD) and diabetes mellitus were independent risk factors for QREC colonization/infection. A single FQ course significantly increases the risk of QREC colonization/infection for no less than two years. This risk is higher in cases of multiple courses, longer hospital stays, COPD and diabetes; in males; and in older patients. These findings may inform public campaigns and courses directed to prescribers to promote rational antibiotic use.

Indexed as

anti-bacterial agentsantimicrobial resistancebacterialdrug resistanceEscherichia colifluoroquinolonesinformation storage and retrievalprimary carequinolones

Identifiers

PMID35740228
PMCPMC9219874
OpenAlexW4283079972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.